Transcend Therapeutics

Transcend Therapeutics, founded in 2021, is a clinical-stage, neuroscience-focused company developing rapid-acting treatments for neuropsychiatric diseases. Our mission is to develop new drugs for the millions of people for whom current psychiatric medicines have not worked. Our leadership team has made pivotal contributions to 13 FDA approvals (including recent MDD approval),$3.5B in M&A, and significant public company value creation. As a Public Benefit Corporation, we have pledged 10% of founding shares toward nonprofits focused on scientific research and access.